For the significant eQTL for CDKN2B (rs9632884), lower gene expression correlated with lower eGFR, consistent with our preclinical data in which greater blockade of CDK4/6, the target of palbociclib and CDKN2A/B, was protective in CKD (Table 1). Here, CDKN2A is linked to chronic kidney disease.